Cargando…

Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study

AIM: Data from a local quality registry are used to model the risk of late xerostomia after radiotherapy for head and neck cancer (HNC), based on dosimetric- and clinical variables. Strengths and weaknesses of using quality registry data are explored. METHODS: HNC patients treated with radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Onjukka, Eva, Mercke, Claes, Björgvinsson, Einar, Embring, Anna, Berglund, Anders, Alexandersson von Döbeln, Gabriella, Friesland, Signe, Gagliardi, Giovanna, Lenneby Helleday, Clara, Sjödin, Helena, Lax, Ingmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456883/
https://www.ncbi.nlm.nih.gov/pubmed/32923404
http://dx.doi.org/10.3389/fonc.2020.01647
_version_ 1783575886573862912
author Onjukka, Eva
Mercke, Claes
Björgvinsson, Einar
Embring, Anna
Berglund, Anders
Alexandersson von Döbeln, Gabriella
Friesland, Signe
Gagliardi, Giovanna
Lenneby Helleday, Clara
Sjödin, Helena
Lax, Ingmar
author_facet Onjukka, Eva
Mercke, Claes
Björgvinsson, Einar
Embring, Anna
Berglund, Anders
Alexandersson von Döbeln, Gabriella
Friesland, Signe
Gagliardi, Giovanna
Lenneby Helleday, Clara
Sjödin, Helena
Lax, Ingmar
author_sort Onjukka, Eva
collection PubMed
description AIM: Data from a local quality registry are used to model the risk of late xerostomia after radiotherapy for head and neck cancer (HNC), based on dosimetric- and clinical variables. Strengths and weaknesses of using quality registry data are explored. METHODS: HNC patients treated with radiotherapy at the Karolinska University hospital are entered into a quality registry at routine follow up, recording morbidity according to a modified RTOG/LENT-SOMA scale. Other recorded parameters are performance status, age, gender, tumor location, tumor stage, smoking status, chemotherapy and radiotherapy data, including prescribed dose and organ-at-risk (OAR) dose. Most patients are entered at several time points, but at variable times after treatment. Xerostomia was modeled based on follow-up data from January 2014 to October 2018, resulting in 753 patients. Two endpoints were considered: maximum grade ≥2 (XER(G≥2)) or grade ≥3 (XER(G≥3)) late xerostomia. Univariate Cox regression was used to select variables for two multivariate models for each endpoint, one based on the mean dose to the total parotid volume (D(tot)) and one based on the mean dose to the contralateral parotid (D(contra)). Cox regression allows the estimation of the risk of xerostomia at different time points; models were presented visually as nomograms estimating the risk at 9, 12, and 24 months respectively. RESULTS: The toxicity rates were 366/753 (49%) for XER(G≥2) and 40/753 (5.3%) for XER(G≥3). The multivariate models included several variables for XER(G≥2), and dose, concomitant chemotherapy and age were included for XER(G≥3). Induction chemotherapy and an increased number of fractions per week were associated with a lower risk of XER(G≥2). However, since the causality of these relationships have limited support from previous studies, alternative models without these variables were also presented. The models based on the mean dose to the total parotid volume and the contralateral parotid alone were very similar. CONCLUSION: Late xerostomia after radiotherapy can be modeled with reasonable predictive power based on registry data; models are presented for different endpoints highly relevant in clinical practice. However, the risk of modeling indirect relationships, given the unavoidably heterogeneous registry data, needs to be carefully considered in the interpretation of the results.
format Online
Article
Text
id pubmed-7456883
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74568832020-09-11 Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study Onjukka, Eva Mercke, Claes Björgvinsson, Einar Embring, Anna Berglund, Anders Alexandersson von Döbeln, Gabriella Friesland, Signe Gagliardi, Giovanna Lenneby Helleday, Clara Sjödin, Helena Lax, Ingmar Front Oncol Oncology AIM: Data from a local quality registry are used to model the risk of late xerostomia after radiotherapy for head and neck cancer (HNC), based on dosimetric- and clinical variables. Strengths and weaknesses of using quality registry data are explored. METHODS: HNC patients treated with radiotherapy at the Karolinska University hospital are entered into a quality registry at routine follow up, recording morbidity according to a modified RTOG/LENT-SOMA scale. Other recorded parameters are performance status, age, gender, tumor location, tumor stage, smoking status, chemotherapy and radiotherapy data, including prescribed dose and organ-at-risk (OAR) dose. Most patients are entered at several time points, but at variable times after treatment. Xerostomia was modeled based on follow-up data from January 2014 to October 2018, resulting in 753 patients. Two endpoints were considered: maximum grade ≥2 (XER(G≥2)) or grade ≥3 (XER(G≥3)) late xerostomia. Univariate Cox regression was used to select variables for two multivariate models for each endpoint, one based on the mean dose to the total parotid volume (D(tot)) and one based on the mean dose to the contralateral parotid (D(contra)). Cox regression allows the estimation of the risk of xerostomia at different time points; models were presented visually as nomograms estimating the risk at 9, 12, and 24 months respectively. RESULTS: The toxicity rates were 366/753 (49%) for XER(G≥2) and 40/753 (5.3%) for XER(G≥3). The multivariate models included several variables for XER(G≥2), and dose, concomitant chemotherapy and age were included for XER(G≥3). Induction chemotherapy and an increased number of fractions per week were associated with a lower risk of XER(G≥2). However, since the causality of these relationships have limited support from previous studies, alternative models without these variables were also presented. The models based on the mean dose to the total parotid volume and the contralateral parotid alone were very similar. CONCLUSION: Late xerostomia after radiotherapy can be modeled with reasonable predictive power based on registry data; models are presented for different endpoints highly relevant in clinical practice. However, the risk of modeling indirect relationships, given the unavoidably heterogeneous registry data, needs to be carefully considered in the interpretation of the results. Frontiers Media S.A. 2020-08-14 /pmc/articles/PMC7456883/ /pubmed/32923404 http://dx.doi.org/10.3389/fonc.2020.01647 Text en Copyright © 2020 Onjukka, Mercke, Björgvinsson, Embring, Berglund, Alexandersson von Döbeln, Friesland, Gagliardi, Lenneby Helleday, Sjödin and Lax. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Onjukka, Eva
Mercke, Claes
Björgvinsson, Einar
Embring, Anna
Berglund, Anders
Alexandersson von Döbeln, Gabriella
Friesland, Signe
Gagliardi, Giovanna
Lenneby Helleday, Clara
Sjödin, Helena
Lax, Ingmar
Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study
title Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study
title_full Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study
title_fullStr Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study
title_full_unstemmed Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study
title_short Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study
title_sort modeling of xerostomia after radiotherapy for head and neck cancer: a registry study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456883/
https://www.ncbi.nlm.nih.gov/pubmed/32923404
http://dx.doi.org/10.3389/fonc.2020.01647
work_keys_str_mv AT onjukkaeva modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT merckeclaes modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT bjorgvinssoneinar modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT embringanna modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT berglundanders modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT alexanderssonvondobelngabriella modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT frieslandsigne modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT gagliardigiovanna modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT lennebyhelledayclara modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT sjodinhelena modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy
AT laxingmar modelingofxerostomiaafterradiotherapyforheadandneckcanceraregistrystudy